This work is licensed under a Creative Commons Attribution 4.0 International License.
A4K14-citropin1.1-Sp4
General Information
DRACP ID DRACP05891
Peptide Name A4K14-citropin1.1-Sp4
Sequence GLFAVIKKⓍASVⓍKGL
Sequence Length 16
UniProt ID Not available
PubChem CID Not available
Origin Synthetic
Type Synthetic peptide
Classification
Cancer targeted peptides Stapled Peptides Membrane-targeted
Activity Information
| Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
|---|---|---|---|---|---|---|
| C4-2B | Prostate carcinoma | Carcinoma | IC50=8.90 μM | CCK-8 assay | 96 h | 1 |
| A549 | Lung adenocarcinoma | Carcinoma | IC50=10.51 μM | CCK-8 assay | 96 h | 1 |
| U87 | Glioblastoma | Blastoma | IC50=7.277 μM | CCK-8 assay | 96 h | 1 |
| MCF-7 | Invasive breast carcinoma of no special type | Carcinoma | IC50=10.49 μM | CCK-8 assay | 96 h | 1 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer
Structure Information
Helicity 85.3
Linear/Cyclic Cyclic (Stapled)
Disulfide/Other Bond Stapled: Ⓧ are cross-linked by hydrocarbon stapling
N-terminal Modification Acetylation
C-terminal Modification Amidation
Other Modification Ⓧ=(S)-2-(4-pentenyl)alanine
Chiral L
Physicochemical Information
Formula C68H115N17O14
Absent amino acids CDEHMNPQRTWY
Common amino acids K
Mass 166251
Pl 11.1
Basic residues 3
Acidic residues 0
Hydrophobic residues 8
Net charge 3
Boman Index 1127
Hydrophobicity 85
Aliphatic Index 121.88
Half Life
/
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 3
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 33363118
Title Design, Synthesis, and Antitumor Activities Study of Stapled A4K14-Citropin 1.1 Peptides
Year 2020
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available
This work is licensed under a Creative Commons Attribution 4.0 International License.